Φορτώνει......
CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ(c) cytokine stimulation via PI3K/mTOR axis
Obinutuzumab is a glycoengineered tumor-targeting anti-CD20 mAb with a modified crystallizable fragment (Fc) domain designed to increase the affinity for the FcγRIIIA/CD16 receptor, which was recently approved for clinical use in CLL and follicular lymphoma. Here we extend our previous observation t...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Immunol Immunother |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7113231/ https://ncbi.nlm.nih.gov/pubmed/31950225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02482-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|